Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Other Non-current Assets
Long-term assets not reported separately.
Evommune, Inc.NYSE: EVMN
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets turns negative
Q1 FY2026 other non-current assets was -$2.13M, compared with $61K a year earlier.
Context
- Other non-current assets amounted to 0.7% of total assets at the end of Q1 FY2026, up 0.6 pp from a year earlier.
- Other non-current assets increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether other non-current assets keeps falling in the next quarterly balance sheet after a -3593.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 101K USD
- Year-over-year change
- +65.6%
- 2-year CAGR
- +51.5%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 101K | +65.6% |
| FY2024 | 2024-12-31 | 61K | +38.6% |
| FY2023 | 2023-12-31 | 44K | — |
Other Non-current Assets vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 other non-current assets of -$2.13M is the lowest of the 10 companies compared; the peer median is $1.53M.
- Its year-over-year change of -3593.5% is the lowest of 10, against a peer median of +93.9%.
- Other non-current assets amounts to 0.7% of total assets for EVMN, versus a peer median of 1.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $217.54M | +703.7% | +1.0% | 10.0% | |
FTREFortrea Holdings Inc. | Jun 2026 | $91.8M | -9.4% | +14.2% | 3.4% |
| Sep 2026 | $27.24M | +268.8% | — | 2.3% | |
| Mar 2026 | $18.94M | +214.2% | +365.4% | 6.6% | |
CLYMClimb Bio, Inc. | Mar 2026 | $1.53M | +577.0% | +128.6% | 1.0% |
| Mar 2026 | $1.36M | -26.4% | -25.6% | 0.5% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $919K | +93.9% | +21.1% | 0.9% |
| Mar 2026 | $594K | -70.7% | +10.1% | 0.5% | |
| Mar 2026 | $267K | -84.1% | -25.0% | 0.2% | |
EVMNEvommune, Inc. | Mar 2026 | -$2.13M | -3593.5% | — | 0.7% |
| Peer median (excluding EVMN) | $1.53M | +93.9% | +12.1% | 1.0% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.